Evidence map›Paper›PMID 35488243›Full record

ReviewJournal of hematology & oncology2022

Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies.

Yuting Lu, Xiangliang Yuan, Miao Wang, Zhihao He, Hongzhong Li, Ji Wang, Qin Li

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of hematology & oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 329 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
329citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

329 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. IntratumorGut microbes · 2026
    Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Bidirectional Modulation of the Tumor Immune Microenvironment by Gut Microbiota-Derived Indoles: Mechanisms and Therapeutic Potential.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  17. Article
  18. Review
  19. Review
  20. Article

269 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuting LuDepartment of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.
Xiangliang YuanDepartment of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Miao WangDepartment of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.
Zhihao HeDepartment of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.
Hongzhong LiChongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Ji WangNational Institute of TCM Constitution and Preventive Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China. doctorwang2009@126.com.
Qin LiDepartment of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China. qinli128003@ccmu.edu.cn.

Funding

General program of National Natural Science Foundation of China 82174243National Natural Science Foundation of China 81301912the Beijing Municipal Health and Scientific and Technological Achievements and Appropriate Technology Promotion Project BHTPP202008the General program of National Natural Science Foundation of China 81973715the "High-value Patent Cultivation" project of the Beijing Friendship Hospital Affiliated to the Capital Medical University YYZSCQ202003the Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine ZYYCXTD-C-202001the Research Foundation of Beijing Friendship Hospital YYQDKT2019-40
6 · The paper itself

Abstract

The gut microbiota have long been recognized to play a key role in human health and disease. Currently, several lines of evidence from preclinical to clinical research have gradually established that the gut microbiota can modulate antitumor immunity and affect the efficacy of cancer immunotherapies, especially immune checkpoint inhibitors (ICIs). Deciphering the underlying mechanisms reveals that the gut microbiota reprogram the immunity of the tumor microenvironment (TME) by engaging innate and/or adaptive immune cells. Notably, one of the primary modes by which the gut microbiota modulate antitumor immunity is by means of metabolites, which are small molecules that could spread from their initial location of the gut and impact local and systemic antitumor immune response to promote ICI efficiency. Mechanistic exploration provides novel insights for developing rational microbiota-based therapeutic strategies by manipulating gut microbiota, such as fecal microbiota transplantation (FMT), probiotics, engineered microbiomes, and specific microbial metabolites, to augment the efficacy of ICI and advance the age utilization of microbiota precision medicine.

Indexed as

Gastrointestinal MicrobiomeMicrobiotaFecal Microbiota TransplantationHumansImmunityImmunotherapyCancer immunotherapyGut microbiotaImmune checkpoint inhibitorsMicrobiota-derived metabolitesTherapeutic strategies

Identifiers

PMID35488243
PMCPMC9052532

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.